Dataset Information

Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures.

ABSTRACT: Targeted treatment of advanced melanoma could benefit from the precise molecular characterization of melanoma samples. Using a melanoma-specific selection of 217 genes, we performed targeted deep sequencing of a series of biopsies, from advanced melanoma cases, with a Breslow index of ? 4 mm, and/or with a loco-regional infiltration in lymph nodes or presenting distant metastasis, as well of a collection of human cell lines. This approach detected 3-4 mutations per case, constituting unique mutational signatures associated with specific inhibitor sensitivity. Functionally, case-specific combinations of inhibitors that simultaneously targeted MAPK-dependent and MAPK-independent mechanisms were most effective at inhibiting melanoma growth, against each specific mutational background. These observations were challenged by characterizing a freshly resected biopsy from a metastatic lesion located in the skin and soft tissue and by testing its associated therapy ex vivo and in vivo using melanocytes and patient-derived xenografted mice, respectively. The results show that upon mutational characterization of advanced melanoma patients, specific mutational profiles can be used for selecting drugs that simultaneously target several deregulated genes/pathways involved in tumor generation or progression.

SUBMITTER: Curiel-Olmo S

PROVIDER: S-EPMC4694844 | biostudies-other | 2015 Sep

REPOSITORIES: biostudies-other

ACCESS DATA

Publications

Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures.

Curiel-Olmo Soraya S García-Castaño Almudena A Vidal Rebeca R Pisonero Helena H Varela Ignacio I León-Castillo Alicia A Trillo Eugenio E González-Vela Carmen C García-Diaz Nuria N Almaraz Carmen C Moreno Thaidy T Cereceda Laura L Madureira Rebeca R Martinez Nerea N Ortiz-Romero Pablo P Valdizán Elsa E Piris Miguel A MA Vaqué José P JP

Oncotarget 20150901 28

Targeted treatment of advanced melanoma could benefit from the precise molecular characterization of melanoma samples. Using a melanoma-specific selection of 217 genes, we performed targeted deep sequencing of a series of biopsies, from advanced melanoma cases, with a Breslow index of ≥ 4 mm, and/or with a loco-regional infiltration in lymph nodes or presenting distant metastasis, as well of a collection of human cell lines. This approach detected 3-4 mutations per case, constituting unique muta ...[more]

PMID: 26327537

Similar Datasets

Project description:Much emphasis has been placed on the identification, functional characterization, and therapeutic potential of somatic variants in tumor genomes. However, the majority of somatic variants lie outside coding regions and their role in cancer progression remains to be determined. In order to establish a system to test the functional importance of non-coding somatic variants in cancer, we created a low-passage cell culture of a metastatic melanoma tumor sample. As a foundation for interpreting functional assays, we performed whole-genome sequencing and analysis of this cell culture, the metastatic tumor from which it was derived, and the patient-matched normal genomes. When comparing somatic mutations identified in the cell culture and tissue genomes, we observe concordance at the majority of single nucleotide variants, whereas copy number changes are more variable. To understand the functional impact of non-coding somatic variation, we leveraged functional data generated by the ENCODE Project Consortium. We analyzed regulatory regions derived from multiple different cell types and found that melanocyte-specific regions are among the most depleted for somatic mutation accumulation. Significant depletion in other cell types suggests the metastatic melanoma cells de-differentiated to a more basal regulatory state. Experimental identification of genome-wide regulatory sites in two different melanoma samples supports this observation. Together, these results show that mutation accumulation in metastatic melanoma is nonrandom across the genome and that a de-differentiated regulatory architecture is common among different samples. Our findings enable identification of the underlying genetic components of melanoma and define the differences between a tissue-derived tumor sample and the cell culture created from it. Such information helps establish a broader mechanistic understanding of the linkage between non-coding genomic variations and the cellular evolution of cancer.

Dataset Information

Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures.

Publications

Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure